Prof. F. Alameda Quitllet

University of Barcelona, Spain

Email: FAlameda@parcdesalutmar.cat

Qualifications

1977 M.D., Autonomous University of Barcelona

Publications (selected)

1. ALAMEDA F, Lloveras B, Pijuan L., “Ancillary techniques for the diagnosis of glandular lesions of the female,” genital tract, Monogr Clin Cytol, 2011; 20: 101-6.
2. ALAMEDA F, Mariñoso ML, Bellosillo B, Muset M, Pairet S, Soler I, Romero E, Larrazabal F, Carreras R, Serrano S., “Detection of HPV by in situ hybridizatioon in thin-layer (ThinPrep) cervico-vaginal samples,” Tumour Biol, 2001 Feb, 8 Epub ahead of print.
3. F.ALAMEDA, L. Pijuan, B. LLoveras, E. Romero, R.Carreras, S.serrano., “Axillary metastasis in a patient with double neoplasia. Case report.” Acta Cytol, 2010; 54: 1133-1135.
4. J.Planagumá, M.Liljeström, F.ALAMEDA, R.Butzow, I.Virtanen, J.Reventos  M. Hukkanen, “MMP-2 and MMP-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian Carcinoma,” Human Pathology, 2011; 42(1): 57-67.
5. Membrilla Fernández E, Pares D, ALAMEDA F, Pascual M, Courtier R, Gil MJ, Vallecillo G, Fusté P, Pera M, Grande L., “Anal Intrarepithelial Neoplasia: application of a diagnostic protocol in risk patients using anal cytology”, Cir Esp 2009, Mar 19. PMID: 19303590.
6. M. Monge, E. Colas, A. Doll, A. Gil-Moreno. J. Castellvi, B. Diaz, M. Gonzalez, R. Lopez-Lopez, J. Xercavins, R. Carreras, F. ALAMEDA, F. Canals, F. Gabrielli, J.Reventós, M.Abal , “Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress”, Carcinogenesis. Aceptado, en prensa (Carcin 2008-01039.R1).
7. Valles X,  Murga GB, Hernandez G, Sabidó M, Chui A, Lloveras B, ALAMEDA F, de San José S, Bosch FX, Pedroza I, Castellsagué X, Casabona J., “High prevalence of HPV infection in female population of Guatemala”, Int J Cancer, 2009 Mar 19. PMID: 19415744.
8. Casamitjana M, Sala M, Ochoa D, Fusté P , Castells X, ALAMEDA F, and SRHCP group, “Results of a cervical cancer screening programme from an area of Barcelona (Spain) with a large immigrant population,” Eur. J. Public Health, 2009 May 12.
9. Doll A, Gonzalez M, Abal M, Llaurado M, Rigau M, Xercavins J, Capella G, Diaz B, Gil-Moreno A, ALAMEDA F, Reventos J., “An Orthotopic endometrial cancer mouse model demonstrates a role of RUNX1 in distant metastases,” Int J Cancer, 2009 Feb 3; 125 (2): 257-263.
10. Fuste P, Bellosillo B, Santamaria X, Mancebo G, Mariñoso L, ALAMEDA F, Espinet B, Sole F, Serrano S, Carreras R., “HPV determination in the control after LEEP due to CIN II-III prospective study and predictive model,” Int J Gynecol Pathol, 2009 Jan 30 Eupub ahead pf print.
11. Costa C, Molina MA, Baró T, Aguilar A, De las Heras P, Fusté P, Mancebo G, Carreras R, Serrano S, ALAMEDA F., “Could the truncated varianbt of ERBB2 be present in the squamous carcinomas of the cervix?” Virchows Arch, 2008 Nov; 453 (5): 535-6. Eupub 2008, sep 26.
12. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colás E, LLauradó M, Alazzouzi H, Planaguma J, Lohmann MA, Garcia J, Castellvi S, Cajal JR, Gil-Moreno , Xercavins J, ALAMEDA F, Reventós J., “Novel molecular profiles of endometrial cancer new light through old windows”, J Steroid Biochem Mol Biol, 2008 Feb; 108(3-5): 221-9.
13. M. Monge, E. Colas, A.Doll, M. Gonzalez, A. Gil-Moreno, J. Planma, M. Quiles, M. A. Arbos, A. Garcia, J. Castellvi, J. Xercavins, F. ALAMEDA, J. Reventos and M. Abal, “ERM/ETV5 up-regulation plays a role during myometrial infiltration through MMP2 activation in endometrial cancer,” Cancer Res, 2007 Jul 15; 67(14): 6753-9.